Storage Stability
Neuropeptide gamma (NPgamma) is a 54-amino-acid N-terminally extended tachykinin derived from the PPT-A (preprotachykinin-A) gene, containing the full neurokinin A sequence at its C-terminus. It is the longest form of the PPT-A-derived tachykinins and shares NK2 receptor preference with neuropeptide K and NKA, but its extended N-terminal domain confers unique stability and tissue distribution properties.
Mechanism of Action
- Longest PPT-A-derived tachykinin; contains identical NKA C-terminus (aa49-54 = NKA core) responsible for NK2 binding
- Extended N-terminus (aa1-48) substantially reduces aminopeptidase degradation, conferring longer duration of action vs NKA
- NK2 agonism in smooth muscle of bronchi, gut, and bladder; NK2 in CNS modulates pain and mood circuits
- May function as a precursor store for NKA via tissue-specific endopeptidase cleavage
- Potency differences between NPgamma, NPK, and NKA at NK2 may relate to conformational presentation of the C-terminal binding domain
Research Findings
- NPgamma demonstrated NK2-mediated bronchoconstriction in isolated guinea pig trachea assays with similar potency to NPK
- Expression pattern of NPgamma shows discrete overlap but not identity with substance P and NKA distribution in rat brain
- Less extensively studied than NPK; most NK2 pharmacology studies use NKA or NPK as reference agonists
- All three PPT-A extended tachykinins (NKA, NPK, NPgamma) present in enteric nervous system and contribute to intestinal motility
- Differential expression of PPT-A splice variants determines relative NPK:NPgamma:NKA ratios in different tissues
Research Protocols
- NK2 bronchoconstriction assay: 1-100 nM NPgamma compared to NKA and NPK as reference agonists
- In vitro gut contractility: isolated ileum or colon smooth muscle bath preparation with 10-1000 nM NPgamma
- Not used clinically; reference agonist in NK2 pharmacology studies only
- Competitive binding assays: 125I-NPgamma or unlabeled as displacement competitor in NK2 binding
Interactions
- NK2 antagonists (MEN10207, GR94800): block NPgamma-mediated smooth muscle contraction
- NEP 24.11 (neprilysin): degrades C-terminal region; NEP inhibitors enhance NPgamma longevity
- Substance P/NKA: co-expressed from same PPT-A gene; coordinate tachykinin neurotransmission
Safety Profile
Endogenous tachykinin. Not used clinically. NK2 agonism contributes to bronchoconstriction and GI hypermotility. NK2 antagonists studied in asthma and IBS have acceptable safety profiles in clinical trials.
Legal & Regulatory
Research peptide; not approved as therapeutic
Ready to dose Neuropeptide Gamma?
Get the exact syringe draw
You have read the research. Now run the math. Pick your vial size and BAC water volume, get IU draw in seconds.
Open the Calculator →
More in Cognitive & Mood
View all →